Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Keeps Halo Pharma to drive independent growth
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
The initiative pairs consumer engagement with a public health message about prevention and early detection
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
Tamir brings more than 20 years of experience in the medical technology sector
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
The summit will bring together 1,200+ delegates, 100+ international faculty from 25 countries
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
